Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest in the medical community because the findings often hold a great deal of promise for new and effective therapies. However, in an article recently published in JAMA, Dartmouth researchers compared the consistency and prominence of interim publications with the final publications.Original Article
You may also like
Pharmaceutical Sales Customer Engagement –...
AstraZeneca’s Polyneuropathy Treatment Recommended...
Designing a Strategic Roadmap for Seamless Product...
AAPS PharmSci 360: LBFs and Tackling Oral Biologic...
CHMP Gives Positive Opinion to Novo Nordisk Hemophilia...
GSK, Cambridge to Partner on R&D for Kidney and...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.